This trial is evaluating whether Vinblastine Sulfate will improve 2 primary outcomes and 1 secondary outcome in patients with Hodgkin Disease. Measurement will happen over the course of 1 year.
This trial requires 118 total participants across 4 different treatment groups
This trial involves 4 different treatments. Vinblastine Sulfate is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
The patient should think the condition is not uncommon. Some patients become infected, but this only occurs with a T-cell mediated, Epstein-Barr virus-positive form of the disease, in a subset of patients who are genetically predisposed or are otherwise at very-high risk. The disease resolves quickly despite the presence of an active infection or the advent of immune-suppression.
It is important to note that, although this disease most commonly affects males, it is becoming increasingly apparent in young and middle-aged females. While HOD may occur spontaneously, there is evidence to suggest an environmental link from x-ray exposure to development of HOD.
While combination chemotherapy with anthracyclines and other antimetabolites, bleomycin, cyclophosphamide, or vincristine are the most commonly used treatment in the majority of adult cases with an unfavorable prognosis, use of anthracyclines alone has become increasingly common among those with an excellent prognosis. As chemotherapy protocols change and new agents such as bortezomib or bexarotene (PXD/VX) become available, treatment regimens may become more personalized for each patient.
There are no recent randomized trial and many case series suggesting for HD, more effective treatment is needed as of right now. In fact in the first cases of HD in which no treatment was recommended, many patients did not survive. [Power(http://www.withpower.com/clinical-trials/hodgkin-disease)] will help you find clinical trials targeted against your HD that will be tailored to your HD, treatment, and location.
The incidence of HD is increasing in the US population. This observation supports the concept that the etiology of HD in the United States is different from that reported in other jurisdictions. The incidence rate of HD in all ages is similar to that reported elsewhere; however, the prevalence rate in young whites is five to sixfold lower. In men, the incidence rate of HD has almost doubled among those age 65 years and older in the United States compared with the incidence in other geographical regions.
There are four types of Hodgkin disease. In each type, there are variations in the cancer cells' genetics, aggressiveness, and appearance. The first is called Mature B-cell lymphoma/leukemia, the second is T-cell lymphoma, the third is lymphomatoid cell lymphoma, and the fourth is a rare form of Hodgkin lymphoma that mostly occurs in Africa and in the Middle East.
If individuals with Hodgkin disease experience the same symptoms as the population, they are unlikely to be at risk of a viral infection. However, if they do experience symptoms that are unusual, they are more likely to be at risk of an infection.
At present, the only [drug that is available for treating hodgkin disease] licensed for clinical use is vinorelbine used in combination with pegylated liposomal [doxorubicin] (trade name Myocet). summary: This article describes the role of ritonavir in treating a human disease.
Several Phase II clinical trials have investigated the potential benefit of v.S. on patients with Stage III Hodgkin disease. One of these, which assessed the benefit of v.S. versus vincristine plus bleomycin in patients with Stage III Hodgkin disease, reported a 5 year disease-free survival rate of 66%. Based upon the available evidence, v.S. may be used for patients with Stage III Hodgkin lymphoma, in combination with current therapeutic approaches.
The overall 5-year cure rate for HD patients was 60% for those with stage I. Stage II patients had a five-year rate of 48% and stage III patients an eight-year rate of 28%. Patients with high-risk features had a poorer survival rate. There is a need to assess the long-term survival rate of these high-risk patients, which is higher in patients treated with ASCT/ACL-B/cRCT. It should be recognized that the improvement in 5-year survival rate in our patients is not related to better treatment of stage IV patients.
This review covers recent research results using new cancer therapies and new clinical trials; thus, it might be useful to surgeons and oncologists to learn the latest research about these therapies.
Based on the evidence available, researchers could recommend the use of vinblastine sulfate in the treatment of stage II or III Hodgkin's lymphoma in combination with other chemotherapy agents based on the level of evidence available. For stage I disease, vinblastine sulfate seems to be a less effective treatment than the currently accepted standard of care regimen with doxorubicin, bleomycin, and vinblastine.